Series A Financing For Annovation Includes Potential Buyout By TMC
This article was originally published in The Pink Sheet Daily
The newest company created under the Atlas Venture Development Corp. model, Annovation, will develop a next-generation anesthetic through proof-of-concept, with investor The Medicines Co. holding an option to acquire the new company.
You may also be interested in...
Biogen participates with Atlas Venture in a $17 million Series A financing for Ataxion, which will seek to advance preclinical ion channel modulators for hereditary ataxias.
Launched in fall 2012 via a partnership between Amgen and Kleiner Perkins Caufield & Byers, the Bay Area biotech has three subsidiary companies housing six biologic assets that used to belong to Amgen. With two financing rounds this year totaling $58.5 million, three candidates are slated to enter the clinic by 2015.
The asset-focused operator of virtual biotechs teamed with Texas early-stage investment group Remeditex to back a new entity. Tigercat has filed an IND to investigate serlopitant for chronic itching.